Mother and son jogging Mother and son jogging Mother and son jogging Mother and son jogging
Advanced Search
  • Jun 3, 2021
    - Abbott has the capacity and supply to support increased demand for mechanical circulatory support (MCS) devices following Medtronic's decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD)
    - Access to MCS devices are critical for advanced heart failure patients and can improve survival, clinical outcomes and quality of life
    - Abbott is working with physicians and health systems to ensure supply of left ventricular assist devices (LVADs) alongside training and education for implanting physicians now offering Abbott's HeartMate 3™ to their patients
  • Jun 1, 2021
    - Updated outlook reflects lower recent and projected demand for COVID-19 tests
    - Revised forecast continues to reflect strong, double-digit EPS growth on both a GAAP and adjusted basis
    - Abbott's base business, excluding COVID-19 testing-related sales, continues to achieve strong growth
    - R&D pipeline continues to be highly productive, with a steady cadence of recent and upcoming product launches across the portfolio
  • May 18, 2021
    - American Heart Association and Abbott announce new initiative to advance health equity, fight high blood pressure and chronic conditions in greater Austin area
  • May 17, 2021
    - Latest-generation TAVI system features advancements to reduce or eliminate risk of blood leakage around valve implant
    - The non-surgical Navitor TAVI system offers best-in-class deliverability and access through small vessels, expanding treatment options for patients with severe aortic stenosis
  • May 12, 2021
    - Newly issued guidance from the U.S. Centers for Disease Control and Prevention now accepts rapid, self-administered testing option that meet its criteria
    - United customers can depart the U.S. with the Abbott BinaxNOW™ Home Test in their carry-on bag and administer the test via the eMed digital health platform to re-enter the U.S.
  • May 6, 2021
    - A new, first-of-its-kind study known as TAP-CHF leverages expertise across Abbott's cardiovascular portfolio to optimize treatment for patients suffering from both AFib and heart failure
    - The trial will utilize Abbott technology including cardiac ablation and sensors to monitor for both pulmonary artery pressure and abnormal heartbeats
    - Historically, treating patients with both AFib and heart failure has been challenging, with few effective treatments or options to adequately manage both conditions simultaneously
  • Apr 26, 2021
    - New imaging platform merges optical coherence tomography (OCT) with the power of automation using artificial intelligence (AI)
    - Ultreon 1.0 Software helps physicians automatically detect and quantify blood vessel characteristics, giving them better insights for optimal patient treatment
    - Platform offers advanced imaging features when combined with the Dragonfly OpStar™ imaging catheter used to access complex anatomy
  • Apr 20, 2021
    - Sales growth of 35.3 percent; organic sales growth of 32.9 percent
    - GAAP diluted EPS growth from continuing operations of 233.3 percent; adjusted diluted EPS growth of 103.1 percent
    - All four major businesses achieved strong sales growth in the quarter
    - Projected full-year EPS remains unchanged; reflects growth of more than 35 percent
  • Apr 19, 2021
    - BinaxNOW is the most studied and widely available rapid antigen test in the U.S. and initially will be available at CVS Pharmacy, Walgreens and Walmart without a prescription
    - Abbott to manufacture tens of millions of BinaxNOW Self Tests per month and can scale capacity upward based on demand
    - The BinaxNOW Self Test will be sold in 2-count packs for an MSRP of $23.99, making it the most affordable over-the-counter (OTC) COVID-19 rapid test available in the U.S.
  • Apr 12, 2021
    - Abbott, Eliud Kipchoge and the NN Running Team collaborate in a partnership to track glucose levels during training and marathons
    - Kipchoge and NN Running Team members will wear Abbott's Libre Sense Glucose Sport Biosensor in upcoming competition at the NN Mission Marathon, the fastest way to the Tokyo Games
    - Built upon the company's world-leading continuous glucose monitoring technology,[i] Abbott's Libre Sense is the world's first glucose biosensor[ii] designed for athletes to help sports performance
Show 5102550100 per page
true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?